These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 34703227)
1. Cetuximab-Modified Human Serum Albumin Nanoparticles Co-Loaded with Doxorubicin and MDR1 siRNA for the Treatment of Drug-Resistant Breast Tumors. Yang X; Wang Y; Chen S; Zhang S; Cui C Int J Nanomedicine; 2021; 16():7051-7069. PubMed ID: 34703227 [TBL] [Abstract][Full Text] [Related]
2. Preparation Optimization of Bovine Serum Albumin Nanoparticles and Its Application for siRNA Delivery. Wang Y; Chen S; Yang X; Zhang S; Cui C Drug Des Devel Ther; 2021; 15():1531-1547. PubMed ID: 33883877 [TBL] [Abstract][Full Text] [Related]
3. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma. Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776 [TBL] [Abstract][Full Text] [Related]
4. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles. Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793 [TBL] [Abstract][Full Text] [Related]
5. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery. Gu J; Fang X; Hao J; Sha X Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500 [TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer. Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555 [TBL] [Abstract][Full Text] [Related]
7. Rational Design of Multifunctional Polymeric Nanoparticles Based on Poly(l-histidine) and d-α-Vitamin E Succinate for Reversing Tumor Multidrug Resistance. Li Z; Chen Q; Qi Y; Liu Z; Hao T; Sun X; Qiao M; Ma X; Xu T; Zhao X; Yang C; Chen D Biomacromolecules; 2018 Jul; 19(7):2595-2609. PubMed ID: 29618203 [TBL] [Abstract][Full Text] [Related]
8. Tumor-targeting pH/redox dual-responsive nanosystem epigenetically reverses cancer drug resistance by co-delivering doxorubicin and GCN5 siRNA. Yuan Y; Liu J; Yu X; Liu X; Cheng Y; Zhou C; Li M; Shi L; Deng Y; Liu H; Wang G; Wang L; Wang Z Acta Biomater; 2021 Nov; 135():556-566. PubMed ID: 34496281 [TBL] [Abstract][Full Text] [Related]
9. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer. Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581 [TBL] [Abstract][Full Text] [Related]
10. EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy. Ye Z; Zhang Y; Liu Y; Liu Y; Tu J; Shen Y Int J Nanomedicine; 2021; 16():2443-2459. PubMed ID: 33814909 [TBL] [Abstract][Full Text] [Related]
11. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer. Wen ZM; Jie J; Zhang Y; Liu H; Peng LP Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938 [TBL] [Abstract][Full Text] [Related]
12. Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymerpolyethylenimine to improve oral squamous carcinoma treatment. Wang D; Xu X; Zhang K; Sun B; Wang L; Meng L; Liu Q; Zheng C; Yang B; Sun H Int J Nanomedicine; 2018; 13():187-198. PubMed ID: 29343957 [TBL] [Abstract][Full Text] [Related]
13. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. Meng H; Mai WX; Zhang H; Xue M; Xia T; Lin S; Wang X; Zhao Y; Ji Z; Zink JI; Nel AE ACS Nano; 2013 Feb; 7(2):994-1005. PubMed ID: 23289892 [TBL] [Abstract][Full Text] [Related]
14. Overcoming Multidrug Resistance by Codelivery of MDR1-Targeting siRNA and Doxorubicin Using EphA10-Mediated pH-Sensitive Lipoplexes: In Vitro and In Vivo Evaluation. Zhang J; Du Z; Pan S; Shi M; Li J; Yang C; Hu H; Qiao M; Chen D; Zhao X ACS Appl Mater Interfaces; 2018 Jun; 10(25):21590-21600. PubMed ID: 29798663 [TBL] [Abstract][Full Text] [Related]
15. Star polyester-based folate acid-targeting nanoparticles for doxorubicin and curcumin co-delivery to combat multidrug-resistant breast cancer. Guo F; Yu N; Jiao Y; Hong W; Zhou K; Ji X; Yuan H; Wang H; Li A; Wang G; Yang G Drug Deliv; 2021 Dec; 28(1):1709-1721. PubMed ID: 34463174 [TBL] [Abstract][Full Text] [Related]
16. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer. Cheng X; Li D; Sun M; He L; Zheng Y; Wang X; Tang R Colloids Surf B Biointerfaces; 2019 Sep; 181():185-197. PubMed ID: 31132609 [TBL] [Abstract][Full Text] [Related]
17. Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with ultrasound. Bai M; Shen M; Teng Y; Sun Y; Li F; Zhang X; Xu Y; Duan Y; Du L Oncotarget; 2015 Dec; 6(41):43779-90. PubMed ID: 26575421 [TBL] [Abstract][Full Text] [Related]
18. Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy. Zhu QL; Zhou Y; Guan M; Zhou XF; Yang SD; Liu Y; Chen WL; Zhang CG; Yuan ZQ; Liu C; Zhu AJ; Zhang XN Biomaterials; 2014 Jul; 35(22):5965-76. PubMed ID: 24768047 [TBL] [Abstract][Full Text] [Related]
19. [Reversing multidrug resistance in breast cancer cell line MCF-7/ADR by small interfering RNA]. Li CB; Zhang F; Shi YR; Wei XY; Yang Y; Niu RF Ai Zheng; 2004 Dec; 23(12):1605-10. PubMed ID: 15601546 [TBL] [Abstract][Full Text] [Related]
20. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors. Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]